References
- Deyo RA, Mirha SK, Martin BI. Back pain prevalence and visits rates. Spine 2006;31:2724-27
- Hart LG, Deyo RA, Cherkin DC. Physician office visits for low back pain. Frequency, clinical evaluation, and treatment patterns from a U.S. national survey. Spine 1995;20:11-19
- Feuerstein M, Marcus SC, Huang GD. National trends in nonoperative care for nonspecific back pain. Spine J 2004;4:56-63
- Goetzel RZ, Hawkins K, Ozminkowski RJ, et al. The health and productivity cost burden of the ‘top 10’ physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med 2003;45:5-14
- Frymoyer JW, Cats-Baril WL. An overview of the incidences and costs of low back pain. Orthop Clin North Am 1991;22:263-71
- Prevalence of disabilities and associated health conditions among adults – United States, 1999. MMWR Morb Mortal Wkly Rep 2001;50:120-5
- Toth PP, Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther 2004;26:1355-67
- Van Tulder M, Becker A, Bekkering T, et al. European guidelines for the management of acute nonspecific low back pain in primary care. Eur Spine J. 2006;15:S169-91
- Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 2004;28:140-75
- Katz WA, Dubé J. Cyclobenzaprine in the treatment of acute muscle spasm: review of a decade of clinical experience. Clin Ther 1988;10:216-28
- Boyles WF, Glassman JM, Soyka JP. Management of acute musculoskeletal conditions: thoracolumbar strain or sprain: a double-blind evaluation comparing the efficacy and safety of carisoprodol with diazepam. Todays Ther Trends 1983;1:1-16
- Rollings HE, Glassman JM, Soyka JP. Management of acute musculoskeletal conditions – thoracolumbar strain or sprain: a double-blind evaluation comparing the efficacy and safety of carisoprodol with cyclobenzaprine hydrochloride. Curr Ther Res 1983;34:917-28
- Watson Pharmaceuticals. Carisoprodol tablets. US prescribing information. Available at: http://pi.watson.com/data_stream.asp?product_group=1213&p=pi&language=E [Last accessed 20 March 2009]
- Soyka JP, Maestripieri LR. Soma compound (carisoprodol plus phenacetin and caffeine) in the treatment of acute, painful musculoskeletal conditions. Curr Ther Res 1979;26:165-80
- Cullen AP. Carisoprodol (Soma) in acute back conditions: a double-blind, randomized, placebo controlled study. Curr Ther Res Clin Exp 1976;20:557-62
- Hindle TH III. Comparison of carisoprodol, butabarbital, and placebo in treatment of the low back syndrome. Calif Med 1972;117:7-11
- Gready DM. Use of carisoprodol in symptomatic therapy of painful muscle spasm. Ind Med Surg 1965;34:617-9
- Ralph L, Look M, Wheeler W, et al. Double-blind, placebo-controlled trial of carisoprodol 250-mg tablets in the treatment of acute lower-back spasm. Curr Med Res Opin 2008;24:551-8
- Roland M, Morris R. A study of the natural history of back pain, Part I: development of a reliable and sensitive measure of disability in low-back pain. Spine 1983;8:141-4
- Borenstein DG, Korn S. Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials. Clin Ther 2003;25:1056-73
- Browning R, Jackson JL, O’Malley PG. Cyclobenzaprine and back pain: a meta-analysis. Arch Intern Med 2001;161:1613-20
- Connelly C. Patients with low back pain: how to identify the few who need extra attention. Postgrad Med 1996;100:143-50,155
- Patel AT, Ogle AA. Diagnosis and management of acute low back pain. Am Fam Physician 2000;61:1779-90
- Burton AK, Erg E. Back injury and work loss. Biomechanical and psychosocial influences. Spine 1997;22:2575-80